Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicenter, Dose Escalation and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05347628 is registered in ClinicalTrials.gov with Avistone Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05347628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05347628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicenter, Dose Escalation and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Avistone Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 25, 2020
Completion date
November 30, 2024
Enrollment
91 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer